Clinuvel Pharmaceuticals reported its 10th consecutive year of profitability for the fiscal year ended June 30, 2026, maintaining revenue above AUD 100 million for the second straight year while increasing cash reserves by AUD 28 million to AUD 252 million.
The company’s shares fell 12.35% in premarket trading to AUD 6.70, following the release of its H2 2026 earnings call transcript on August 27. Total assets reached AUD 295 million, with zero debt marking the 20th consecutive debt-free year. Gross profit margin stood at 83%, while net profit margin reached 36%. Total expenditure was AUD 53.5 million, slightly below the guided annual average of AUD 55 million, with R&D accounting for 35% of total spending and approximately 20% of revenue.
Cash reserves rose despite a AUD 4 million unrealized translation loss due to the appreciation of the Australian dollar against U.S. dollar-denominated term deposits. Surplus cash held in term deposits is earning a 6.23% return. The company also paid its ninth consecutive dividend, equaling 9% of net free cash flow.
Global treatment volumes for SCENESSE increased by 6% year-over-year, with European volumes up 13% and revenue rising 9%. U.S. performance moderated as competitors offered free product through clinical trial programs, though management noted patients eventually returned to SCENESSE after trialing alternatives.
Clinuvel outlined key pipeline developments, including top-line results for its vitiligo program CUV105 expected in Q4 2026, with CUV107 set to begin recruitment in November 2026 and a readout anticipated in 2029. The company plans to submit a European Medicines Agency filing for NEURACTHEL in H2 2026, followed by an FDA filing after the European review process concludes.
Management emphasized North America as Clinuvel’s largest future market, with Managing Director Philippe Wolgen stating the strategic shift aligns with regions where economic activity is concentrated. Chief Financial Officer Peter Vaughan highlighted the company’s balance sheet strength as a key investment case, noting its self-funding, sustainable business model built over a decade of consistent profit growth—a rarity in the life sciences sector.
Clinuvel also confirmed its transition from the ASX to Nasdaq, effective January 1, 2027, as part of its global expansion strategy.
